Subscribe to CarissaRaman.com Subscribe to CarissaRaman.com's comments

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES

 

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it calculated to invite any such offer or invitation. Neither this announcement nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell or a solicitation of any offer to purchase or subscribe for securities in the United States or elsewhere. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will only be made by means of a prospectus that may be obtained from the issuer or selling security holder and that contains detailed information about the issuer and management as well as financial statements. There is no intention to make a public offering of the securities referred to in this announcement in the United States.                                                                   

Almere, The Netherlands
April 24, 2017

ASM International N.V. (Euronext Amsterdam: ASM) (“ASMI”) today announces that it intends to sell a stake of 20 million shares of the total outstanding share capital in ASM Pacific Technology Ltd. (“ASMPT”) through a partial secondary share placement. Following the planned divestment ASMI will own approximately 34% of the shares in ASMPT.

ASMI views long-term value creation as very important. Regularly the Management Board reviews its strategy and, as part of that, the position it holds in ASMPT. The most recent review led to the conclusion that a further reduction of its shareholding of approximately 5% was justified. The Management Board remains of the opinion that, at this moment, a significant stake in ASMPT is of strategic value to ASMI.

Sale of partial stake in ASMPT and use of proceeds 

ASMI is proposing a reduction of its stake in ASMPT through an accelerated bookbuild offering to institutional investors of 20 million shares representing a stake of approximately 5% in ASMPT which is launching now. 

ASMI intends to use the proceeds for a new share buyback program. 

This new share buyback program will be in addition to the one which was announced on March 2, 2017. 

The Hongkong and Shanghai Banking Corporation Limited is acting as bookrunner for this transaction.  

Once the outcome of the offering has been established, ASMI will make a further public announcement. ASMI has agreed to a 180 day lock-up period.


About ASM International

ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International’s common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI’s website at www.asm.com

IMPORTANT NOTICES

The Hongkong and Shanghai Banking Corporation Limited (“HSBC”) is acting for the Company in relation to the transaction, will not regard any other person as a client in relation to the transaction and will not be responsible to anyone other than the Company for providing the protections afforded to clients of HSBC nor for providing advice to any such other person. Without prejudice to liability for fraud, HSBC, its affiliates and its and its and their respective directors, officers, employees and agents disclaim any liability to any such other person in connection with the transaction. 

This announcement is for information purposes only and, save as expressly set out herein, does not constitute an offer or invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities or investment advice in any jurisdiction, including without limitation, the United Kingdom, the United States, Hong Kong, Australia, Canada, Japan, or South Africa. Persons needing advice should consult an independent financial adviser.

This announcement has been issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Bookrunner or by any of its respective affiliates or agents as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.

The distribution of this announcement and the placing of the shares as set out in this announcement in certain jurisdictions may be restricted by law. No action has been taken by the Company or the Bookrunner that would permit an offering of such shares or possession or distribution of this announcement or any other offering or publicity material relating to such shares in any jurisdiction where action for that purpose is required.  Persons into whose possession this announcement comes are required by the Company and the Bookrunner to inform themselves about, and to observe, such restrictions.

This announcement does not constitute a prospectus or an offer or invitation to purchase securities. This announcement is only addressed to, and directed at, persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) as amended by the 2010 PD Amending Directive (Directive 2010/73/EU), as and to the extent implemented in the relevant EEA member state, and any relevant implementing measure in the relevant member state.

In addition, in the United Kingdom, this announcement is not being distributed, nor has it been approved for the purposes of Section 21 of the Financial Services and Markets Act 2000 (“FSMA”), by a person authorised under FSMA and is directed only at, persons (i) who are persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and other persons to whom it may lawfully be communicated (“relevant persons”). Under no circumstances should persons who are not relevant persons rely or act upon the contents of this announcement. Any investment or investment activity to which this announcement relates in the United Kingdom is available only to, and will be engaged only with, relevant persons.

This announcement does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it calculated to invite any such offer or invitation. Neither this announcement nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell or a solicitation of any offer to purchase or subscribe for securities in the United States or elsewhere. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will only be made by means of a prospectus that may be obtained from the issuer or selling security holder and that contains detailed information about the issuer and management as well as financial statements. There is no intention to make a public offering of the securities referred to in this announcement in the United States.

This announcement contains forward-looking statements. These statements are subject to a number of risks and uncertainties and actual results, and events could differ materially from those currently being anticipated as reflected in such forward-looking statements. The terms “expect”, “should be”, “will be” and similar expressions identify forward-looking statements. Factors which may cause future outcomes to differ from those foreseen in forward-looking statements include, but are not limited to: general economic and business conditions; demand for the Company’s products and services; competitive factors in the industries in which the Company operates; exchange rate fluctuations; legislative, fiscal and regulatory developments; political risks; terrorism, acts of war and pandemics; changes in law and legal interpretations affecting the Company’s intellectual property rights and internet communications; and the impact of technological change. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The information contained in this announcement is subject to change without notice and neither the Company nor the Bookrunner assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained herein.

Any indication in this announcement of the price at which ordinary shares have been bought or sold in the past cannot be relied upon as a guide to future performance.  No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The Bookrunner may participate in the Placement on a proprietary basis. 

CONTACT

Investor contact:

Victor Bareño

T: +31 88 100 8500

E: victor.bareno@asm.com

 

Media contact:

Ian Bickerton

T: +31 625 018 512 

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/05ea2ea9-d8c7-41fe-948e-03e004d899c7

Article source: https://globenewswire.com/news-release/2017/04/24/970111/0/en/ASM-INTERNATIONAL-N-V-ANNOUNCES-INTENTION-TO-SELL-PARTIAL-STAKE-OF-APPROXIMATELY-5-IN-ASMPT.html


April 22, 2017, Amsterdam, The Netherlands: Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular carcinoma (HCC). The trial, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, further demonstrated that the cumulative incidence of radiologic progression in the liver as the first event was significantly lower in the SIRT group compared to the sorafenib group (p=0.014), and the response rate was significantly higher in the SIRT group compared to the sorafenib group (19.0% vs 11.6%, p=0.042). Both the side-effect profile and quality of life scores were significantly better over time in the SIRT group compared to the sorafenib group (p=0.005).

Liver cancer, or HCC, is the second most common cause of cancer-related deaths worldwide.1,2 HCC represents more than 90% of primary liver cancers and is a major global health problem.3 The prognosis for patients with advanced liver cancer is poor,2 and the multikinase inhibitor, sorafenib, is the only approved first-line systemic treatment.3 If patients are not tolerant or have contraindications for sorafenib therapy, there is currently no standard of care and patients lack effective treatment options.3 SIRT with yttrium-90 (Y-90) resin microspheres has shown promising anti-tumour results with a safe profile; further trials are needed to establish this treatment as a viable option for patients.3

“Patients with advanced or inoperable hepatocellular carcinoma have a poor prognosis, often with underlying cirrhosis, and the treatment option currently available, sorafenib, has a high level of toxicity. As cohort studies have demonstrated the efficacy of SIRT with Y-90 resin microspheres, we set out to compare the efficacy of this treatment versus the current standard of care,” said Prof Valérie Vilgrain, Hôpital Beaujon Service de Radiologie, Paris, France, and lead author of the study. “While SIRT demonstrated significantly reduced side effects, better quality of life, higher response rates and more effectively controlled tumour progression in the liver, the overall survival of patients was not higher than in the sorafenib group. Nonetheless, this study provides evidence that SIRT may be a better-tolerated alternative for managing this complex and difficult-to-treat disease, deserving further evaluation.”

The SARAH trial was a randomised, controlled, open-label, multicentre investigator initiated Phase 3 trial. Patients with locally advanced or inoperable HCC, who did not respond to other treatments or had two failed rounds of transarterial chemoembolisation, were randomised to SIRT with Y-90 resin microspheres, or oral sorafenib 400 mg twice daily. The primary endpoint of the study was OS and secondary endpoints included progression-free survival (PFS), time to radiological progression at any site and in the liver as the first event, tumour response, quality of life, and safety and toxicity.

There were 459 patients from 25 French clinical centres included in the study, 237 of whom received SIRT. Median PFS was 4.1 months and 3.7 months in the SIRT and sorafenib groups, respectively (p=0.765). Cumulative incidence of radiological progression at any site did not differ in either group (p=0.256). Overall, there were 1,297 and 2,837 treatment-related adverse events (AEs) including 230 and 411 grade ?3, in the SIRT and sorafenib groups, respectively. The number of patients with at least one treatment-related adverse event was 173 (76.5%) and 203 (94.0%), (p

“The SARAH trial is the first reported randomised controlled trial evaluating the survival benefit of SIRT in locally advanced HCC compared to sorafenib. SIRT was found to be safe, but regrettably the study failed meet the primary endpoint and SIRT did not show an overall survival superior to sorafenib. Further trials are needed to establish this treatment as a viable option for patients,” said Prof Alejandro Forner, BCLC group, Liver Unit, Hospital Clinic Barcelona, Spain and EASL Governing Board Member.

###

Yttrium-90 resin microspheres

Y-90 resin microspheres are miniscule radioactive ‘beads’ that are used in SIRT. They contain the radioactive component yttrium-90. These microspheres are injected in huge quantities into the liver tumours, where they become stuck in the small blood vessels that are in and around the tumours. The microspheres then emit high doses of radiation, which enable doctors to deliver up to 40 times more radiation to the liver tumours than would be possible using standard radiation therapy, all while sparing surrounding healthy tissue.4

About The International Liver Congress™

This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. The International Liver Congress™ 2017 will take place from April 19 – 23, at the RAI Amsterdam, Amsterdam, The Netherlands.

About The European Association for the Study of the Liver (EASL)

Since its foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European Association with international influence, with an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

Contact

For more information, please contact the ILC Press Office at:

  • Email: ILCpressoffice@ruderfinn.co.uk
  • Telephone: +44 (0)7841 009 252

Onsite location reference

Session title: General session III and award ceremony II

Time, date and location of session: 10:00 – 12:00, Saturday 22 April, Hall 5

Presenter: Valérie Vilgrain, France

Abstract: SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma (GS012), 10:00 – 10:15

Author disclosures

Speaker fees: Guerbet, SIRTEX, Supersonic, Toshiba. SIRTEX: Funding of SARAH trial. Guerbet: Study Investigator.

References

1 World Health Organization. Cancer. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. Last accessed: April 2017.

2 World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Last accessed: April 2017.

3 EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.

4 Sirtex Medical Liminted. About SIR-Spheres microspheres. Available from: http://www.sirtex.com/us/patients/about-sir-spheres-microspheres/. Last accessed: April 2017.

Article source: https://www.eurekalert.org/pub_releases/2017-04/eaft-sib041217.php


Article source: http://qns.com/story/2017/04/24/family-friendly-new-amsterdam-festival-coming-ridgewoods-historic-onderdonk-house/


Editor’s note: The Anne Frank Museum in Amsterdam, the Netherlands, hosts an invitation-only seminar every spring for teachers and students from multiple countries. This year, the Anne Frank Inspire Academy in San Antonio was selected as one of 12 international schools – and the first U.S. school – to participate.

The 2017 seminar theme was “Youth Voices Today: Exploring Identity through Creative Writing” and focused on the educational value of Anne Frank’s diary, connecting her words to classrooms around the world. In observance of Holocaust Remembrance Day, here are first-person accounts from the Anne Frank Inspiration Academy facilitator, Carrie Ross, and ninth grade student, Zoe Luca.

Photo RNW.org / Creative Commons

The Anne Frank Museum in Amsterdam, the Netherlands.

Thoughts from Carrie Ross (Anne Frank Inspire Academy Facilitator)

I have always wanted to travel internationally. The cultures, ethnic food, and historic locations have piqued my interest for as long as I can remember. Back in college, I was this close to spending a semester abroad in Cork, Ireland. Through a series of unfortunate events, my passport was packed away in a keepsake box, and a few years later I entered the field of education working to open up worlds of possibilities for my students through teaching literature. Looking back now, it seems almost serendipitous that I would find myself drawn to San Antonio’s Anne Frank Inspire Academy and have the chance to dig out that old passport and dust it off.

Article source: https://therivardreport.com/local-delegation-inspired-by-anne-frank-seminar/


Hyatt has announced the opening of Hyatt Regency Amsterdam, the first Hyatt Regency hotel to open in The Netherlands’ dynamic capital city. Hyatt Regency Amsterdam is the third Hyatt-branded hotel in The Netherlands, joining luxury lifestyle hotel Andaz Amsterdam Prinsengracht and select service hotel Hyatt Place Amsterdam Airport.

“The opening of Hyatt Regency Amsterdam marks a significant milestone for the Hyatt Regency brand as it continues to expand its footprint throughout Europe”, said Peter Fulton, group president – Europe, Africa and Middle East, Hyatt. “The hotel is an ideal location for both business and leisure travelers visiting Amsterdam and nicely complements Andaz Amsterdam Prinsengracht and Hyatt Place Amsterdam Airport.”
 
Located in the center of Amsterdam, bordering the energizing East district and right at the heart of Plantage Amsterdam, Hyatt Regency Amsterdam is designed to connect business and leisure travelers to all Amsterdam has to offer. The hotel is nearby some of the city’s best museums, shopping and dining – with easy access to the city’s Metro trains and tram lines, guests can enjoy top sites including Rijksmuseum, Dam Square and Canal Ring. Additionally, the hotel is located less than 10 minutes from Amsterdam RAI Exhibition and Convention Center, and 20 minutes from Amsterdam Airport Schiphol.
 
“At Hyatt Regency Amsterdam, we set the stage for dynamic interactions – from a quick coffee meeting to shared culinary experiences, our guests can come together to socialize, collaborate or celebrate,” said Toni Hinterstoisser, general manager for both Hyatt Regency Amsterdam and Andaz Amsterdam Prinsengracht. “We are confident that the hotel’s spacious accommodations, premier meeting facilities and superior service will provide an authentic experience and one-stop convenience to business and leisure travelers.”
 
Guestrooms
Hyatt Regency Amsterdam has been thoughtfully designed, blending history with a modern-day 24/7 lifestyle. The hotel’s 211 guestrooms, including 15 suites, range in size from 322 square feet (30 square meters) for a standard room to 1,356 square feet (126 square meters) for the Spinoza Suite. Inspired by the invigorating greenery of the hotel’s surroundings that is home to leafy boulevards, the city’s botanical garden and ARTIS Amsterdam Royal Zoo, each guestroom is elegantly decorated with blooming floral and botanical artwork. Flexible furnishings, a generous workspace, large windows, and a striking bathroom with soothing walk-in rain shower complete the guest experience.
 
Authentic Culinary Experiences
Seamlessly flowing out of the lobby, on-site restaurant and bar Mama Makan is the vibrant heart of the hotel’s drinking and dining experience. Evoking the atmosphere of a grand café inspired by the dining and sitting rooms of Jakarta, head chef Paul Verheul and his team take guests and locals on an enticing culinary journey. Bringing together authentic and bold aromas and tastes, Mama Makan is a fusion of traditional Dutch café fare and Indonesian specialties that make a great start or end to the day.
 
The bar is an extension of this captivating space, mixing up daring cocktails inspired by well-travelled spices, herbs and plants. This is also the place for a freshly brewed Javanese-style coffee or an ice-cold drink. When weather permits, the Mama Makan experience will be extended to the hotel terrace, where food and drinks can be enjoyed with the Dutch summer breeze.??
The hotel’s 24-hour café-style market offers one-stop experience for guests to eat and drink whenever and wherever they would like. The market provides a wide selection of refreshing beverages along with delicious homemade pastries and bakery items.??
Event Venues
Boosting more than 5,565 square feet (517 square meters) of flexible meeting and event facilities, Hyatt Regency Amsterdam provides cleverly designed spaces with abundant natural daylight and top-of-the-line audiovisual equipment that can cater all occasions – meetings to conferences, weddings to social events.
 
The hotel’s main event venue is the 2,055-square-foot (191-square-meter) ballroom with eye catching oak wood flooring and floor-to-ceiling windows that overlook the Singelgracht canal. The ballroom is accessible by a separate entrance and is unrivalled in versatility – from seminars to weddings and festive gala dinners, the modern design of the room offers endless opportunities for customizable layouts. The inviting, adjacent foyer is ideal for coffee breaks, breakout sessions or to lounge and connect with others.
 
For smaller groups, Hyatt Regency Amsterdam offers three individual event rooms that can be used individually or can be connected. Sophisticated by design, these meeting rooms provide ample space and flexibility for engaging meetings of any sort.
 
Health and Wellness
Hyatt Regency Amsterdam provides guests with various options to refresh and re-energize, including a 24-hour fully equipped fitness center and sauna. Additionally, guests can enjoy a variety of nearby jogging trails for a run through the city or the nearby Oosterpark.

Submit to DiggSubmit to DiggSubmit to FacebookSubmit to FacebookSubmit to Google PlusSubmit to Google PlusSubmit to StumbleuponSubmit to StumbleuponSubmit to TwitterSubmit to TwitterSubmit to LinkedInSubmit to LinkedIn

Article source: https://www.incentivetravel.co.uk/hotel/38935-hyatt-regency-amsterdam-marks-the-debut-of-hyatt-regency-brand-in-the-netherlands


Tentoonstelling ‘Een Betere Stad. Amsterdam en het Algemeen Uitbreidingsplan. 1935, 1958, 2006, 2017.’ Over het AUP, dat ontw…

Article source: https://evenementen.amsterdam.nl/


April 22, 2017, Amsterdam, The Netherlands: Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular carcinoma (HCC). The trial, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, further demonstrated that the cumulative incidence of radiologic progression in the liver as the first event was significantly lower in the SIRT group compared to the sorafenib group (p=0.014), and the response rate was significantly higher in the SIRT group compared to the sorafenib group (19.0% vs 11.6%, p=0.042). Both the side-effect profile and quality of life scores were significantly better over time in the SIRT group compared to the sorafenib group (p=0.005).

Liver cancer, or HCC, is the second most common cause of cancer-related deaths worldwide.1,2 HCC represents more than 90% of primary liver cancers and is a major global health problem.3 The prognosis for patients with advanced liver cancer is poor,2 and the multikinase inhibitor, sorafenib, is the only approved first-line systemic treatment.3 If patients are not tolerant or have contraindications for sorafenib therapy, there is currently no standard of care and patients lack effective treatment options.3 SIRT with yttrium-90 (Y-90) resin microspheres has shown promising anti-tumour results with a safe profile; further trials are needed to establish this treatment as a viable option for patients.3

“Patients with advanced or inoperable hepatocellular carcinoma have a poor prognosis, often with underlying cirrhosis, and the treatment option currently available, sorafenib, has a high level of toxicity. As cohort studies have demonstrated the efficacy of SIRT with Y-90 resin microspheres, we set out to compare the efficacy of this treatment versus the current standard of care,” said Prof Valérie Vilgrain, Hôpital Beaujon Service de Radiologie, Paris, France, and lead author of the study. “While SIRT demonstrated significantly reduced side effects, better quality of life, higher response rates and more effectively controlled tumour progression in the liver, the overall survival of patients was not higher than in the sorafenib group. Nonetheless, this study provides evidence that SIRT may be a better-tolerated alternative for managing this complex and difficult-to-treat disease, deserving further evaluation.”

The SARAH trial was a randomised, controlled, open-label, multicentre investigator initiated Phase 3 trial. Patients with locally advanced or inoperable HCC, who did not respond to other treatments or had two failed rounds of transarterial chemoembolisation, were randomised to SIRT with Y-90 resin microspheres, or oral sorafenib 400 mg twice daily. The primary endpoint of the study was OS and secondary endpoints included progression-free survival (PFS), time to radiological progression at any site and in the liver as the first event, tumour response, quality of life, and safety and toxicity.

There were 459 patients from 25 French clinical centres included in the study, 237 of whom received SIRT. Median PFS was 4.1 months and 3.7 months in the SIRT and sorafenib groups, respectively (p=0.765). Cumulative incidence of radiological progression at any site did not differ in either group (p=0.256). Overall, there were 1,297 and 2,837 treatment-related adverse events (AEs) including 230 and 411 grade ?3, in the SIRT and sorafenib groups, respectively. The number of patients with at least one treatment-related adverse event was 173 (76.5%) and 203 (94.0%), (p

“The SARAH trial is the first reported randomised controlled trial evaluating the survival benefit of SIRT in locally advanced HCC compared to sorafenib. SIRT was found to be safe, but regrettably the study failed meet the primary endpoint and SIRT did not show an overall survival superior to sorafenib. Further trials are needed to establish this treatment as a viable option for patients,” said Prof Alejandro Forner, BCLC group, Liver Unit, Hospital Clinic Barcelona, Spain and EASL Governing Board Member.

###

Yttrium-90 resin microspheres

Y-90 resin microspheres are miniscule radioactive ‘beads’ that are used in SIRT. They contain the radioactive component yttrium-90. These microspheres are injected in huge quantities into the liver tumours, where they become stuck in the small blood vessels that are in and around the tumours. The microspheres then emit high doses of radiation, which enable doctors to deliver up to 40 times more radiation to the liver tumours than would be possible using standard radiation therapy, all while sparing surrounding healthy tissue.4

About The International Liver Congress™

This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. The International Liver Congress™ 2017 will take place from April 19 – 23, at the RAI Amsterdam, Amsterdam, The Netherlands.

About The European Association for the Study of the Liver (EASL)

Since its foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European Association with international influence, with an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

Contact

For more information, please contact the ILC Press Office at:

  • Email: ILCpressoffice@ruderfinn.co.uk
  • Telephone: +44 (0)7841 009 252

Onsite location reference

Session title: General session III and award ceremony II

Time, date and location of session: 10:00 – 12:00, Saturday 22 April, Hall 5

Presenter: Valérie Vilgrain, France

Abstract: SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma (GS012), 10:00 – 10:15

Author disclosures

Speaker fees: Guerbet, SIRTEX, Supersonic, Toshiba. SIRTEX: Funding of SARAH trial. Guerbet: Study Investigator.

References

1 World Health Organization. Cancer. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. Last accessed: April 2017.

2 World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Last accessed: April 2017.

3 EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.

4 Sirtex Medical Liminted. About SIR-Spheres microspheres. Available from: http://www.sirtex.com/us/patients/about-sir-spheres-microspheres/. Last accessed: April 2017.

Article source: https://www.eurekalert.org/pub_releases/2017-04/eaft-sib041217.php


In 2017, Holland America Line will celebrate its 70th year in Alaska and to commemorate the milestone, the cruise line has planned experiences and events that will take place on every Alaska cruise and on the Land+Sea Journeys

In addition to entertainment that was created especially for the anniversary, Holland America Line will also debut a new Alaska-centric menu with dishes created by the line’s Culinary Council, two anniversary Alaska Beers, commemorative gifts and more. 

New Onboard Entertainment 

In partnership with BBC Earth, a new Alaska in Concert multimedia production will premiere. The production will combine a live music set against a backdrop of footage from the BBC Earth television series, Wild Alaska. In addition, Holland America Line will showcase Native Voices, a program of Huna cultural interpretation while cruising through Glacier Bay National Park

Cuisine and Culinary Shows

The main dining room will showcase special decor and customized menus that celebrate the cruise line’s Alaskan heritage. The menu will offer new dishes created by Holland America Line’s Master Chef Rudi Sodamin and the company’s Culinary Council composed of chefs Jonnie Boer, David Burke, Elizabeth Falkner and Jacques Torres. A 70th Anniversary Baked Alaska will top off the celebratory meal. 

Two New Alaska Brews

For the 70th Anniversary Celebration, the company will expand its selection of beers by introducing a customized, exclusive Holland America Line Pale Ale. Another anniversary beer by Denali Brewing Company will be available at Denali for guests on Land+Sea Journeys. 

New Ship

To make it possible for more guests to cruise to Alaska with Holland America Line in 2017, the company added a seventh ship to the region to fill demand. Starting this spring, MS Amsterdam, MS Eurodam, MS Nieuw Amsterdam, MS Noordam, MS Oosterdam, MS Volendam and MS Zaandam will offer a total of 135 Alaska departures. 

Visit www.hollandamerica.com

 

 

Article source: http://www.travelagentcentral.com/cruises/holland-american-marks-70th-year-alaska-events-entertainment


Bon splitting the protons of techno.

Bon Spengler works as a DJ and promoter and is a key player on the online radio station and label Proton Radio. She is one of the gatekeepers of the local techno scene and one of the loudest cheerleaders for the many talented DJs and producers emerging in Dallas.

Spengler is know for techno and house, but for this week’s mixtape she goes full robot for a hot mix of techno. It’s the same sound she throws down at her “Nothing but Techno” residency, which has become a weekly oasis for lovers of the genre.

Nothing but Techno has moved venues a few times, but it found a home at Crown and Harp last year. Now that Crown and Harp is closing May 7, Spengler will be moving locations again.

It’s been a few years since you have done a mix for us. How has deejaying changed or evolved for you over that time?
2016 was a busy year for me. We threw 70 events, and I played over 30 of them. I’m feeling like I have house music down for sure; I’ve now evolved into refining other sounds that interest me. And because of the internet, music is abundant these days, so having confidence in your track selection is key.

How was this mix made and was there a theme behind it?
This mix was recorded at Crown and Harp. Typically for a 10 p.m. opening slot, I mostly warm up with deep dubby techno, then feel my way through. … For this mix, I ended with minimal ghetto tech breaks, because I was inspired by that old sound, and the next DJ was playing acid techno breaks after me.

How did Nothing but Techno get started at Crown and Harp?
It actually got started at our warehouse October 2012 with local techno DJs from DFW, including Ill 76, me, James Kelly and Planet Dubois. Next, I brought in two good friends from Denver: John Templeton and Missing Link. Then Luis Flores, Kyle Geiger, Mike Parker, Convextion and so forth until 2015. Then I had an opportunity to do one Thursday night a month at Absinthe Lounge at South Side on Lamar. Finally in 2016, we moved to the Crown and Harp [but next month they will] shut the doors for good.

What’s new with Proton Radio? Do you have an electronic music label?
Proton Radio has reached over to the label distribution side called Proton Soundsystems, handling contracts, distribution and royalties’ management. If you want to learn more about what we do for independent labels, go to soundsystem.protonradio.com/+/. Proton Radio and Beatport also teamed up for Crates, which is an electronic music browser made by DJs for DJs. Try it out.

What is your relationship with techno?
Actively involved … we kiss daily.

Are there any genres you would like to play more of?
Ambient and synth wave

Are you involved in any production?
Yes. Hello Humanoids with my partner Sam Proton, using Ableton.

Where do you like to dig for tracks? Online or in stores?
I use Crates, which I talked about earlier, and also rummage through promos sent to my email daily. Mostly, I love to hunt music on Bandcamp, or hit up thrift stores for classic vinyl.

Which new producers have been getting you excited?
I saw an electronic jazz trio called AMBIQ at a vegan music festival deep in jungle of Tulum and been following them since. Also love this girl from France who goes by Hydrangea.

What has been your most significant music experience of the past year?
It feels pretty cool to hang out with your American friends at parties in foreign countries. Last year going to Amsterdam Dance Event or ADE for the first time was rad. It’s a lot like SXSW with loads of activities for electronic music fans, and finally getting to meet my Proton Radio European colleagues in person was a plus. … I also used the unique opportunity to see DJs that don’t ever tour the United States. So far this year, though, the jungle party in Tulum was memorable, and I’m looking toward the upcoming Movement festival in Detroit. …This is a must for me; Detroit is always a significant time.

What gigs do you have coming up?
For April 2017, the last two parties for Nothing but Techno at Crown and Harp. On April 28, I’m opening for Doubting Thomas at Ethics Lounge [Austin], tagging b2b with my partner as KAMAPALA. As for NBT, it continues on… . We’re finalizing details for the new Nothing but Techno podcast show.

Tracklist:
01. Coppice Halifax – “Jel Gun (Original Mix)” [Milieu Music]
02. Substak Shebuzzz – “In A Sea (Matthias Springer Remix)” [Dimbideep Music]
03. Schulz Audio – “Seti (Original Mix)” [Hello Strange]
04. Schulz Audio – “Zatar (Original Mix)” [Hello Strange]
05. Leftover – “Desolate Plains (Original Mix)” [Baum]
06. Andrey Pushkarev – “Before The End (Original Mix)” [Endless]
07. Donato Dozzy – “Cassandra (Original Mix)” [Claque Musique]
08. Boris. – “What I See (Original Mix)” [Conceptual]
09. Suolo – “Direct Inapoi (Original Mix)” [Minimalaysia]
10. Butr Mark Thibideau – “Serge 4.0 (Original Mix)” [Paperface]
11. Jim-E Stack – “Run (Original Mix)” [Innovative Leisure]
12. Treescape – “Modul (Original Mix)” [Sleep Is Commercial]
13. Pierre Codarin – “Concrete (Original Mix)” [No Idea's Original]
14. Pablo Bolivar – “The Spark (Versalife aka Conforce)” [Curle Recordings]
15. Blawan – “Kaz (Original Mix)” [RS Records]
16. Colo – “Never Again (George FitzGerald Remix)” [Take Records]
17. A1 Bassline – “Shock Headed (Original Version)” [Tighten Up Records]
18. Ion Driver – “Magma (Original Mix)” [Digital Distortions]
19. Dexter – “Fat Skinny People (Original Mix)” [Clone Crown Limited Series]
20. Vlad Onu – “Utterly Amazing (Alien Pimp Remix)” [DubKraft Records]
21. Savage Skulls – “No. 1 Spot (Chaos in the CBD Remix)” [Enchufada]
22. E.B.E. – “Stratus (Original Mix)” [Manuscript Records Ukraine]
23. Ion Driver – “Magma (Original Mix)” [Digital Distortions]
24. Ribbon Tweeter Worship – “Blacktop Beauty (Oilpanic Remix)” [530Techno]

Article source: http://www.dallasobserver.com/music/dallas-observer-mixtape-with-bon-spengler-9386818


In 2017, Holland America Line will celebrate its 70th year in Alaska and to commemorate the milestone, the cruise line has planned experiences and events that will take place on every Alaska cruise and on the Land+Sea Journeys

In addition to entertainment that was created especially for the anniversary, Holland America Line will also debut a new Alaska-centric menu with dishes created by the line’s Culinary Council, two anniversary Alaska Beers, commemorative gifts and more. 

New Onboard Entertainment 

In partnership with BBC Earth, a new Alaska in Concert multimedia production will premiere. The production will combine a live music set against a backdrop of footage from the BBC Earth television series, Wild Alaska. In addition, Holland America Line will showcase Native Voices, a program of Huna cultural interpretation while cruising through Glacier Bay National Park

Cuisine and Culinary Shows

The main dining room will showcase special decor and customized menus that celebrate the cruise line’s Alaskan heritage. The menu will offer new dishes created by Holland America Line’s Master Chef Rudi Sodamin and the company’s Culinary Council composed of chefs Jonnie Boer, David Burke, Elizabeth Falkner and Jacques Torres. A 70th Anniversary Baked Alaska will top off the celebratory meal. 

Two New Alaska Brews

For the 70th Anniversary Celebration, the company will expand its selection of beers by introducing a customized, exclusive Holland America Line Pale Ale. Another anniversary beer by Denali Brewing Company will be available at Denali for guests on Land+Sea Journeys. 

New Ship

To make it possible for more guests to cruise to Alaska with Holland America Line in 2017, the company added a seventh ship to the region to fill demand. Starting this spring, MS Amsterdam, MS Eurodam, MS Nieuw Amsterdam, MS Noordam, MS Oosterdam, MS Volendam and MS Zaandam will offer a total of 135 Alaska departures. 

Visit www.hollandamerica.com

 

 

Article source: http://www.travelagentcentral.com/cruises/holland-american-marks-70th-year-alaska-events-entertainment